Bank of America Corp DE decreased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 35.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 202,508 shares of the company's stock after selling 113,458 shares during the period. Bank of America Corp DE owned about 0.36% of Harmony Biosciences worth $6,968,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of HRMY. Vanguard Group Inc. grew its stake in shares of Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after acquiring an additional 1,262,362 shares during the last quarter. Marshall Wace LLP boosted its position in Harmony Biosciences by 165.2% in the fourth quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock valued at $31,992,000 after buying an additional 579,103 shares during the last quarter. Norges Bank purchased a new stake in Harmony Biosciences in the fourth quarter valued at approximately $16,118,000. Pacer Advisors Inc. boosted its position in Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after buying an additional 351,582 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Harmony Biosciences by 173.9% in the fourth quarter. Invesco Ltd. now owns 449,180 shares of the company's stock valued at $15,456,000 after buying an additional 285,156 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.
Harmony Biosciences Stock Performance
NASDAQ:HRMY traded up $0.33 during trading hours on Friday, reaching $34.38. The company had a trading volume of 531,767 shares, compared to its average volume of 608,730. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The firm has a market cap of $1.97 billion, a PE ratio of 16.29, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The business's 50 day moving average price is $31.54 and its 200-day moving average price is $33.98. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.19. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's quarterly revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.67 EPS. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.
Analyst Ratings Changes
A number of brokerages recently commented on HRMY. Mizuho upped their target price on Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a research report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group dropped their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Harmony Biosciences presently has an average rating of "Buy" and a consensus target price of $52.78.
Get Our Latest Analysis on Harmony Biosciences
Harmony Biosciences Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Articles
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
